The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment

Eur Urol. 1996;29(4):413-9. doi: 10.1159/000473789.


Objectives: To investigate the outcome of neo-adjuvant hormone treatment before radical prostatectomy regarding local tumour extension, peri-operative blood loss and operation time.

Patients: Of 111 surgically treated patients with prostate cancer (T1b-T3a, N0, M0, G1-3), 55 were randomised to immediate radical prostatectomy and 56 to 3 months of neo-adjuvant treatment with triptorelin (3.75 mg i.m. every 28 days) and cyproterone acetate (50 mg b.i.d. for 3 weeks to prevent flare).

Results: No differences were found in blood loss or operation time but patients who had neo-adjuvant treatment had a significantly lower frequency of positive margins (41 vs. 23%, p = 0.013).

Conclusion: Neo-adjuvant treatment does not facilitate radical prostatectomy but may improve the chance of local cure. This must, however, be documented with long-term follow-up in randomised patients.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Androgen Antagonists / therapeutic use
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Blood Loss, Surgical
  • Chemotherapy, Adjuvant
  • Cyproterone Acetate / therapeutic use
  • Humans
  • Male
  • Neoplasm Staging
  • Prostate / pathology
  • Prostate-Specific Antigen / blood
  • Prostatectomy*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / surgery*
  • Testosterone / blood
  • Time Factors
  • Triptorelin Pamoate / therapeutic use*


  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal
  • Triptorelin Pamoate
  • Testosterone
  • Cyproterone Acetate
  • Prostate-Specific Antigen